Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs ALFUZOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Local infiltration anesthesia for dental procedures,Nerve block anesthesia for dental procedures
Treatment of benign prostatic hyperplasia (BPH),Off-label: Management of ureteral stones (medical expulsive therapy)
Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
Articaine: terminal half-life ~20 minutes (0.33 h) in plasma; clinical context: rapid elimination limits systemic toxicity. Epinephrine: short half-life ~2 minutes; clinical effect terminated by uptake and metabolism.
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Articaine is primarily metabolized by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid. Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Extensively metabolized in the liver, primarily via CYP3A4, to inactive metabolites.
Articaine is primarily metabolized by plasma esterases; its inactive metabolite articainic acid is excreted renally (approximately 90% as metabolites, <2% unchanged). Epinephrine is metabolized by COMT and MAO; metabolites and small amounts unchanged are excreted in urine (~90% renal).
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Articaine: ~60–80% bound to plasma proteins (primarily albumin). Epinephrine: ~50% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
82-90% bound to human serum albumin and alpha-1-acid glycoprotein.
Articaine: Vd ~1.0 L/kg (healthy adults); large Vd indicates extensive tissue distribution. Epinephrine: Vd ~0.2 L/kg (predominantly in circulation and tissues).
Approximately 2.5-3.2 L/kg; indicates extensive extravascular distribution.
Not applicable for submucosal injection (100% bioavailable locally). Oral epinephrine has negligible bioavailability due to first-pass metabolism. For systemic effects, IV administration yields 100% bioavailability.
Oral immediate-release: 64% (first-pass metabolism); extended-release: 49% relative to immediate-release.
No dosage adjustment required for mild-to-moderate renal impairment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of articaine metabolite; monitor for toxicity.
For Cr Cl 30-49 m L/min: 10 mg once daily; for Cr Cl <30 m L/min: contraindicated.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reduced doses and monitor for prolonged effects.
Child-Pugh A: 10 mg once daily; Child-Pugh B or C: contraindicated.
Children ≥4 years: 4% articaine with 1:100,000 or 1:200,000 epinephrine; submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 7 mg/kg (absolute max 500 mg). For 1:100,000 formulation, maximum epinephrine dose 0.001 mg/kg (0.001 m L/kg) per injection.
Not established; safety and efficacy in children <18 years have not been studied.
No specific dose adjustment; consider reduced doses due to age-related decreased hepatic and renal function; monitor for prolonged anesthesia and cardiovascular effects; use lowest effective dose.
No specific dose adjustment recommended; monitor for orthostatic hypotension and dizziness.
Not available
None.
Risk of methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency or hemoglobin abnormalities,Use with caution in patients with cardiovascular disease, hypertension, or hyperthyroidism due to epinephrine component,Avoid intravascular injection; may cause systemic toxicity or cardiovascular collapse,Caution in patients with hepatic or renal impairment,May cause allergic reactions or hypersensitivity; cross-sensitivity with other amide anesthetics is possible
Risk of hypotension, especially orthostatic hypotension, particularly with dose initiation or increase,May cause syncope, especially in patients with predisposing factors (e.g., hypovolemia, concurrent antihypertensives),Use with caution in patients with hepatic impairment,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on or previously treated with alpha-1 blockers,Should not be used in combination with other alpha-1 blockers
Hypersensitivity to articaine, epinephrine, or any component of the formulation,Hypersensitivity to amide-type local anesthetics,Patients with severe uncontrolled hypertension or hyperthyroidism,Patients with known sulfite sensitivity (epinephrine contains sodium metabisulfite),Do not use in patients with paroxysmal tachycardia or other serious arrhythmias
Hypersensitivity to alfuzosin hydrochloride or any component of the formulation,Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir),Moderate to severe hepatic impairment (Child-Pugh B or C)
No known food-drug interactions. Avoid eating until numbness resolves to prevent oral trauma.
Take with food to reduce the risk of hypotension. Avoid grapefruit juice as it may increase alfuzosin levels. High-fat meals may alter absorption; consistency in meal timing is advised.
FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. Risk to fetus cannot be ruled out. Use only if clearly needed. No specific trimester-associated risks identified; however, epinephrine may reduce uteroplacental blood flow, particularly if given with vasoconstrictors or during second/third trimester.
Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. First trimester: no evidence of fetal harm from animal data. Second and third trimesters: potential risk of maternal hypotension affecting uteroplacental perfusion; limited human data available.
Articaine and epinephrine are excreted into breast milk in low amounts. M/P ratio not available. The American Academy of Pediatrics considers articaine compatible with breastfeeding. However, theoretical risk of cardiovascular effects in infant exists. Use with caution, and advise mother to pump and discard milk for 4-6 hours after administration to minimize exposure.
It is unknown if alfuzosin is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised due to potential for adverse effects in nursing infants, including hypotension. Alternative agents with more safety data are preferred during breastfeeding.
No specific dose adjustment required based on pharmacokinetic changes in pregnancy. However, due to increased plasma volume and cardiac output, higher doses may be needed to achieve adequate anesthesia? Typically, lowest effective dose is recommended. Avoid excessive epinephrine (max 0.1 mg per appointment) to minimize risk of uteroplacental vasoconstriction.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, increased plasma volume during pregnancy may reduce drug levels; clinical effect should be monitored. Use lowest effective dose if necessary, and avoid in patients with severe hypotension or hypovolemia.
Aspirate before injection to prevent intravascular administration. Maximum dose: 7 mg/kg articaine (0.175 m L/kg of 4% solution with 1:100,000 epinephrine). Avoid in patients with hepatic porphyria. Use with caution in patients with sulfite allergy (epinephrine component contains sodium metabisulfite).
Alfuzosin is a selective alpha-1 adrenergic antagonist used for benign prostatic hyperplasia (BPH). It has fewer cardiovascular side effects than other alpha-blockers due to its higher affinity for alpha-1a receptors in the prostate. Do not use in patients with moderate to severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Use with caution in patients with prolonged QT interval or on QT-prolonging drugs. Administer after the same meal each day to reduce first-dose syncope.
You may experience temporary numbness of the tongue, lips, or face; avoid eating or drinking until sensation returns to prevent biting yourself.,Do not drive or operate machinery for at least 2 hours after administration, or until numbness resolves.,Contact your dentist or doctor immediately if you experience chest pain, difficulty breathing, rapid heartbeat, or severe headache after injection.,Inform your healthcare provider if you have heart disease, high blood pressure, thyroid problems, or are taking MAO inhibitors or tricyclic antidepressants.
Take this medication immediately after a meal at the same time each day.,Avoid situations that may cause dizziness or fainting, especially after the first dose or when increasing dose.,Do not crush, chew, or open the tablet; swallow whole.,Do not drive or operate heavy machinery until you know how the medication affects you.,Inform your doctor if you experience severe dizziness, fainting, or irregular heartbeat.,Avoid alcohol, which can increase dizziness and blood pressure-lowering effects.,Do not take with other alpha-blockers or medications for erectile dysfunction without consulting your doctor.
"The concurrent use of acepromazine, a phenothiazine neuroleptic with significant α1-adrenergic receptor antagonism, and articaine, an amide local anesthetic, may result in enhanced hypotensive and arrhythmogenic effects. Acepromazine-induced vasodilation and decreased peripheral resistance, combined with articaine's potential for myocardial depression and conduction disturbances, particularly in cases of inadvertent intravascular injection, can precipitate severe hypotension and ventricular arrhythmias. Additionally, phenothiazines can potentiate the central nervous system depressant effects of local anesthetics, increasing the risk of sedation and respiratory depression."
"Coadministration of articaine, an amide local anesthetic that inhibits voltage-gated sodium channels, and levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may increase the risk of adverse cardiovascular effects, particularly hypertension and arrhythmias. The SNRI's enhancement of norepinephrine activity can potentiate sympathomimetic responses, while articaine's sodium channel blockade may exacerbate conduction abnormalities. This combination requires caution due to potential for additive cardiotoxicity."
"Dextropropoxyphene, a centrally acting opioid analgesic, may cause additive central nervous system depression and respiratory depression when combined with articaine, a local anesthetic. This interaction can lead to profound sedation, respiratory compromise, and increased risk of bradycardia and hypotension. Co-administration requires careful patient monitoring to prevent serious adverse outcomes, especially in elderly or debilitated patients."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, can enhance the antihypertensive effect of Benidipine, a dihydropyridine calcium channel blocker. This occurs through additive vasodilation, potentially leading to excessive reductions in blood pressure. Clinically, patients may experience orthostatic hypotension, dizziness, or syncope, particularly during initial co-administration or dose adjustments."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, may potentiate the hypotensive effects of lamotrigine, an anticonvulsant. This interaction is primarily due to additive vasodilation, leading to an increased risk of orthostatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or with dose adjustments. Patients, especially those with cardiovascular comorbidities, should be monitored for blood pressure changes and symptoms of hypotension."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, reduces peripheral vascular resistance by blocking alpha-1 receptors on vascular smooth muscle. Pentolinium, a ganglionic blocker, inhibits sympathetic outflow by competitively blocking nicotinic acetylcholine receptors at autonomic ganglia, leading to pronounced hypotension. When combined, their additive vasodilatory effects can cause excessive hypotension, increased risk of syncope, dizziness, and potential cardiovascular collapse, especially during initial therapy or dose escalation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs ALFUZOSIN HYDROCHLORIDE, answered by our medical review team.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is a Alpha/Beta Agonist that works by Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.. ALFUZOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and ALFUZOSIN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is: Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.. The standard adult dose of ALFUZOSIN HYDROCHLORIDE is: 10 mg orally once daily immediately after the same meal each day. Extended-release tablet.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and ALFUZOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is classified as Category A/B. FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. ALFUZOSIN HYDROCHLORIDE is classified as Category C. Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.